Related Experiment Video

Updated: May 15, 2026

Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

Alexander Shimabukuro-Vornhagen1, Andreas Draube, Tanja Liebig

  • 1Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, D-50924 Cologne, Germany.

Oncology Reports
|January 8, 2013
PubMed

Insights

Prostaglandin E2 (PGE2) does not hinder the effectiveness of CD40-activated B cells in cancer immunotherapy. These B cells remain potent antigen-presenting cells, even in the presence of tumor-derived immunosuppressive factors.

Area of Science:

  • Immunology
  • Cancer Research
  • Cell Biology

Background:

  • Tumor vaccination is a promising cancer immunotherapy.
  • Tumors evade immune responses via immunosuppression, often mediated by Prostaglandin E2 (PGE2).
  • PGE2 suppresses immune cells like T cells, macrophages, and dendritic cells (DCs).

Purpose of the Study:

  • To investigate the impact of PGE2 on CD40-activated human B cells.
  • To determine if PGE2 affects the phenotype, migration, and antigen-presenting capacity of these B cells.
  • To assess the potential of CD40-activated B cells as antigen-presenting cells in the tumor microenvironment.

Main Methods:

  • Activation of human B cells using CD40.
  • Treatment of activated B cells with PGE2.
  • Analysis of B cell phenotype, migratory potential, and antigen-presenting function.

Main Results:

  • PGE2 did not alter the immunostimulatory properties of CD40-activated B cells.
  • The antigen-presenting capacity of B cells remained unaffected by PGE2.
  • CD40-activated B cells maintain their potential as cellular adjuvants.

Conclusions:

  • CD40-activated B cells are robust against PGE2-mediated immunosuppression.
  • These B cells are suitable for use as cellular adjuvants in cancer immunotherapy.
  • Their efficacy is maintained even in tumor microenvironments rich in PGE2.

More Related Videos

Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.